22019-66-5Relevant articles and documents
MRGX Receptor Antagonists
-
Paragraph 0380-0382, (2021/05/07)
The invention relates to a method for preventing or treating a disease or disorder that is associated with the MrgX2 receptor. The invention also relates to MrgX2 antagonists and physiologically acceptable salts thereof. The invention also relates to pharmaceutical compositions and dosage forms comprising an MrgX2 antagonist.
Regioselective Nitration of N-Alkyl Anilines using tert-Butyl Nitrite under Mild Condition
Chaudhary, Priyanka,Gupta, Surabhi,Muniyappan, Nalluchamy,Sabiah, Shahulhameed,Kandasamy, Jeyakumar
, p. 104 - 119 (2019/01/08)
Regioselective ring nitration of N-alkyl anilines is reported using tert-butyl nitrite. The reactions proceed efficiently with a wide range of substrates providing synthetically useful N-nitroso N-alkyl nitroanilines in excellent yields which can be easily converted into N-alkyl phenylenediamines and N-alkyl nitroanilines using Zn-AcOH and HCl/MeOH, respectively.
Phenylquinoxalinone CFTR activator as potential prosecretory therapy for constipation
Cil, Onur,Phuan, Puay-Wah,Son, Jung-Ho,Zhu, Jie S.,Ku, Colton K.,Tabib, Niloufar Akhavan,Teuthorn, Andrew P.,Ferrera, Loretta,Zachos, Nicholas C.,Lin, Ruxian,Galietta, Luis J.V.,Donowitz, Mark,Kurth, Mark J.,Verkman, Alan S.
, p. 14 - 4,26 (2017/03/22)
Constipation is a common condition for which current treatments can have limited efficacy. By high-throughput screening, we recently identified a phenylquinoxalinone activator of the cystic fibrosis transmembrane conductance regulator (CFTR) chloride chan
